Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Coherus BioSciences Inc CHRS

Healthcare Biotechnology
Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the research, development and commercialization of immunotherapies to treat cancer. The Company’s immuno-oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor immunologic response and... see more

Recent & Breaking News (NDAQ:CHRS)

Coherus Announces Agreement to Divest UDENYCA® Franchise for up to $558 million to Intas Pharmaceuticals Ltd.

GlobeNewswire 1 day ago

Coherus Management to Participate in the 2024 Citi Global Healthcare Conference

GlobeNewswire 6 days ago

Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire November 6, 2024

Coherus to Report Third Quarter 2024 Financial Results on November 6, 2024

GlobeNewswire October 30, 2024

Coherus BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire August 8, 2024

Coherus to Report Second Quarter 2024 Financial Results on August 8, 2024

GlobeNewswire August 1, 2024

Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction

GlobeNewswire June 27, 2024

Coherus BioSciences Appoints Rita Karachun, CPA, CGMA to its Board of Directors

GlobeNewswire June 5, 2024

Coherus Management to Present at the 2024 Jefferies Global Healthcare Conference

GlobeNewswire May 30, 2024

Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

GlobeNewswire May 23, 2024

Coherus Management to Present at the TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA

GlobeNewswire May 23, 2024

Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire May 9, 2024

Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan

GlobeNewswire May 9, 2024

Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI® (toripalimab-tpzi) with ENB Therapeutics' ENB-003 for the Treatment of Ovarian Cancer

GlobeNewswire May 8, 2024

Coherus to Report First Quarter 2024 Financial Results on May 9, 2024

GlobeNewswire May 1, 2024

Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

GlobeNewswire April 24, 2024

Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting

GlobeNewswire April 8, 2024

Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update

GlobeNewswire March 13, 2024

Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024

GlobeNewswire March 5, 2024

Coherus Completes Divestiture of Ophthalmology Franchise

GlobeNewswire March 4, 2024